Axitinib modulates hypoxia-induced blood–retina barrier permeability and expression of growth factors

References

• Ablonczy Z, Crosson CE. 2007. VEGF modulation of retinal pigment epithelium resistance. Exp Eye Res. 85 6: 762–771.
   PubMed Web of Science ®Google Scholar
• Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, . 1995. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA. 92 23: 10457–10461.
   PubMed Web of Science ®Google Scholar
• Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW. 1998. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: Vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes. 47 12: 1953–1959.
   PubMed Web of Science ®Google Scholar
• Bailey TA, Kanuga N, Romero IA, Greenwood J, Luthert PJ, Cheetham ME. 2004. Oxidative stress affects the junctional integrity of retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 45 2: 675–684.
   PubMedGoogle Scholar
• Betsholtz C, Karlsson L, Lindahl P. 2001. Developmental roles of platelet-derived growth factors. Bioessays. 23 6: 494–507.
   PubMed Web of Science ®Google Scholar
• Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, . 1997. Vascular permeability factor/vascular endothelial growth factor: A multifunctional angiogenic cytokine. EXS. 79:233–269.
   PubMedGoogle Scholar
• Chappelow AV, Kaiser PK. 2008. Neovascular age-related macular degeneration: Potential therapies. Drugs. 68 8: 1029–1036.
   PubMed Web of Science ®Google Scholar
• Cui J, Lei H, Samad A, Basavanthappa S, Maberley D, Matsubara J, . 2009. PDGF receptors are activated in human epiretinal membranes. Exp Eye Res. 88 3: 438–444.
   PubMed Web of Science ®Google Scholar
• Cunha-Vaz JG, Shakib M, Ashton N. 1966. Studies on the permeability of the blood–retinal barrier. I. On the existence, development, and site of a blood–retinal barrier. Br J Ophthalmol. 50 8: 441–453.
   PubMedGoogle Scholar
• Ehrlich R, Harris A, Kheradiya NS, Winston DM, Ciulla TA, Wirostko B. 2008. Age-related macular degeneration and the aging eye. Clin Interv Aging. 3 3: 473–482.
   PubMed Web of Science ®Google Scholar
• Ehrlich R, Harris A, Ciulla TA, Kheradiya N, Winston DM, Wirostko B. 2010. Diabetic macular oedema: Physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmol. 88 3: 279–291.
   PubMed Web of Science ®Google Scholar
• Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, . 2004. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. Faseb J. 18 2: 338–340.
   PubMed Web of Science ®Google Scholar
• Grisanti S, Tatar O. 2008. The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res. 27 4: 372–390.
   PubMed Web of Science ®Google Scholar
• Haines JL, Schnetz-Boutaud N, Schmidt S, Scott WK, Agarwal A, Postel EA, . 2006. Functional candidate genes in age-related macular degeneration: Significant association with VEGF, VLDLR, and LRP6. Invest Ophthalmol Vis Sci. 47 1: 329–335.
   PubMedGoogle Scholar
• Hollborn M, Bringmann A, Faude F, Wiedemann P, Kohen L. 2006. Signaling pathways involved in PDGF-evoked cellular responses in human RPE cells. Biochem Biophys Res Commun. 344 3: 912–919.
   PubMedGoogle Scholar
• Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, . 2006. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol. 168 6: 2036–2053.
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Rixe O. 2010. Axitinib (AG-013736). Recent Results Cancer Res. 184:33–44.
   PubMedGoogle Scholar
• Kernt M, Staehler M, Stief C, Kampik A, Neubauer AS. 2008. Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib treatment. Acta Ophthalmol. 86 4: 456–458.
   PubMed Web of Science ®Google Scholar
• Kernt M, Neubauer AS, Liegl R, Eibl KH, Alge CS, Lackerbauer CA, Ulbig MW, Kampik A. 2009. Cytoprotective effects of a blue light-filtering intraocular lens on human retinal pigment epithelium by reducing phototoxic effects on vascular endothelial growth factor-alpha, Bax, and Bcl-2 expression. J Cataract Refract Surg. 35 2: 354–362.
   PubMed Web of Science ®Google Scholar
• Kernt M, Neubauer AS, Liegl RG, Hirneiss C, Alge CS, Wolf A, Ulbig MW, Kampik A. 2010. Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PlGF. Br J Ophthalmol. 94 11: 1533–1539.
   PubMedGoogle Scholar
• Kevil CG, Okayama N, Trocha SD, Kalogeris TJ, Coe LL, Specian RD, Davis CP, Alexander JS. 1998. Expression of zonula occludens and adherens junctional proteins in human venous and arterial endothelial cells: Role of occludin in endothelial solute barriers. Microcirculation. 5 2–3: 197–210.
   PubMedGoogle Scholar
• Miyamoto N, de Kozak Y, Jeanny JC, Glotin A, Mascarelli F, Massin P, BenEzra D, Behar-Cohen F. 2007. Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: Potential implication in the pathogenesis of diabetic retinopathy. Diabetologia. 50 2: 461–470.
   PubMedGoogle Scholar
• Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 65 1–2: 55–63.
   PubMed Web of Science ®Google Scholar
• Otrock ZK, Mahfouz RA, Makarem JA, Shamseddine AI. 2007. Understanding the biology of angiogenesis: Review of the most important molecular mechanisms. Blood Cells Mol Dis. 39 2: 212–220.
   PubMed Web of Science ®Google Scholar
• Praidou A, Androudi S, Brazitikos P, Karakiulakis G, Papakonstantinou E, Dimitrakos S. 2010. Angiogenic growth factors and their inhibitors in diabetic retinopathy. Curr Diabetes Rev. 6 5: 304–312.
   PubMedGoogle Scholar
• Robbins SG, Mixon RN, Wilson DJ, Hart CE, Robertson JE, Westra I, Planck SR, Rosenbaum JT. 1994. Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. Invest Ophthalmol Vis Sci. 35 10: 3649–3663.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G. 2005. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results. J Clin Oncol. 23 24: 5474–5483.
   PubMed Web of Science ®Google Scholar
• Schlingemann RO. 2004. Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 242 1: 91–101.
   PubMed Web of Science ®Google Scholar
• Schlingemann RO, Oosterwijk E, Wesseling P, Rietveld FJ, Ruiter DJ. 1996. Aminopeptidase a is a constituent of activated pericytes in angiogenesis. J Pathol. 179 4: 436–442.
   PubMed Web of Science ®Google Scholar
• Scholl S, Augustin A, Loewenstein A, Rizzo S, Kupperman B. 2010. General pathophysiology of macular edema. Eur J Ophthalmol. 21 S6: 10–19.
   Google Scholar
• Simo R, Carrasco E, Garcia-Ramirez M, Hernandez C. 2006. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev. 2 1: 71–98.
   PubMedGoogle Scholar
• Simo R, Villarroel M, Corraliza L, Hernandez C, Garcia-Ramirez M. 2010. The retinal pigment epithelium: Something more than a constituent of the blood–retinal barrier – implications for the pathogenesis of diabetic retinopathy. J Biomed Biotechnol. 2010:190724.
   PubMedGoogle Scholar
• Spoerri PE, Afzal A, Li Calzi S, Shaw LC, Cai J, Pan H, . 2006. Effects of VEGFR-1, VEGFR-2, and IGF-IR hammerhead ribozymes on glucose-mediated tight junction expression in cultured human retinal endothelial cells. Mol Vis. 12:32–42.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Saishin Y, Saishin Y, King AG, Levin R, Campochiaro PA. 2009. Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. Arch Ophthalmol. 127 4: 494–499.
   PubMedGoogle Scholar
• The DCCT Research Group. 1991. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med. 90 4: 450–459.
   PubMedGoogle Scholar
• Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. 2000. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 60 2: 203–212.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. 2008. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 7 10: 3129–3140.
   PubMed Web of Science ®Google Scholar
• Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, Girach A. 2004. Epidemiology of diabetic retinopathy and macular oedema: A systematic review. Eye (Lond). 18 10: 963–983.
   PubMed Web of Science ®Google Scholar
• Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. 2003. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 22 1: 1–29.
   PubMed Web of Science ®Google Scholar